Roche announced today, March 21st 2019, that the procedures in the huntingtin lowering trial Generation HD will be changed. Instead of monthly lumbar punctures the participants will only be injected every second month. This means less burden on the participants and on the clinical sites.
The reason for this extraordinary descision is analyzes of data from the ongoing Open Label Extension study with 46 participants from the first Ionis trial where all have been given the active drug for at least 9 months. The investigators found sufficient evidence to conclude that there is no benefit in monthly dosages versus bimonthly. This will most probably make the trial less burdensome for participants as the travel to clinic and the injections will happen only every second month.
You can read the full Roche announcement here